PCSK9 and atherosclerosis: Overall, an estimated 3.2 % (95 % CI, 1.2 %–5.3 %) of US adults with ASCVD were taking ezetimibe or a PCSK9 inhibitor, which represented 5.2 % (95 % CI, 1.9 %–8.6 %) of those recommended add-on therapy.